C. difficile is a spore-forming gram-positive anaerobic bacillus. The risk of colonization and infection is associated with alteration of the normal enteric flora. The most common risk factor is use of broad-spectrum antibiotics; however, use of chemotherapeutic and immunosuppressive agents has also been described [1, 2] . Other risk factors include advanced age, receipt of gastrointestinal surgery, use of nasogastric tubes, receipt of antiperistaltic drugs, and use of proton pump inhibitors [3] [4] [5] .
C. difficile causes human disease by producing at least 2 extracellular toxins: toxin A, which is an enterotoxin, and toxin B, which is a cytotoxin. Gastrointestinal infections can range from mild diarrhea to life-threatening colitis. Management of CDAD involves stopping the inciting agent, if doing so is medically feasible. Diarrhea has been shown to resolve without specific an- timicrobial therapy in 15%-23% of patients with CDAD [6] . For severe disease, antimicrobial therapy directed against C. difficile is required to prevent colonic complications caused by the bacteria. For the majority of cases, metronidazole is considered to be the drug of choice. Relapses, however, occur frequently among patients treated with metronidazole, at a rate of 10%-40% [7] . The routine use of vancomycin, which is similar to metronidazole with respect to efficacy and relapse rates, has been discouraged because of cost and the potential development of vancomycin-resistant enterococci [8] [9] [10] .
To date, no randomized trial to address the use of adjunctive rifampin in addition to metronidazole for the treatment of CDAD has been reported. Rifampin penetrates into cellular materials where organisms may persist and binds strongly to RNA polymerase, inhibiting RNA synthesis. A case series of 7 patients has shown vancomycin and rifampin in combination to be useful in treatment of patients with relapsing CDAD [11] . In addition, rifampin has been shown to have excellent in vitro activity against C. difficile [12] . Furthermore, there have been anecdotal reports of clinicians having more success treating patients with severe CDAD using metronidazole and rifampin, compared with oral metronidazole or vancomycin alone. Such reports indicate that there is quicker resolution of patient symptoms and a reduction in relapse rates with metronidazole and rifampin, compared with standard therapy. Therefore, we performed a prospective, randomized study comparing therapy with metronidazole to therapy with metronidazole and rifampin to define the role of rifampin in the treatment of CDAD. Ontario, Canada). Inclusion criteria consisted of diagnosis of CDAD on the basis of the Society for Healthcare Epidemiology of America definition [13] (diarrhea was defined as the presence of у1 of the following: 6 watery stools within a 36-h period, 3 unformed stools within a 24-h period for at least 2 days, and pseudomembranes seen on endoscopic examination), laboratory confirmation of the presence of C. difficile toxins A and B using an enzyme immunoassay (Techlab TOX A/B II; Techlab), and no other etiology for diarrhea. Exclusion criteria included use of antimicrobial treatment for CDAD for 124 h, age !14 years, known hypersensitivity to study medications, receiving drugs with potential interaction with rifampin (e.g., tacrolimus, cyclosporine, and warfarin), active liver disease (defined by an alanine transaminase level 1200 U/L), adynamic ileus, toxic megacolon, pregnancy, previous diagnosis of CDAD, inability to obtain approval from primary care physician, and inability to provide written, informed consent. All procedures followed were in accordance with the ethical standards of the St. Joseph's Healthcare and Hamilton Health Sciences Research ethics boards and were in accordance with the Helsinki Declaration of 1975, as revised in 1983. Written, informed consent was obtained from patients or their legal representatives.
METHODS

Participants
Intervention. Eligible patients were randomized to receive 500 mg of metronidazole orally 3 times per day for 10 days or 500 mg of metronidazole orally 3 times per day plus 300 mg of rifampin orally 2 times per day for 10 days. Randomization was computer generated, and blinded study staff enrolled patients using numbered packages. The sequence of randomization numbers was concealed until the end of the study. A placebo was not used, because of the potential for additives that may have affected gut motility; thus, participants and those administering the medications were unblinded to treatment.
Assessment of efficacy, follow-up, and outcome measures. The objective of the study was to assess treatment efficacy between the 2 study arms. This was determined by clinical and microbiological criteria. The patient was considered to be clinically cured if he or she became asymptomatic during the treatment course. Clinical failure was defined as persistent symptoms and signs after 10 days of antimicrobial therapy. Clinical relapse was defined as a recurrence of diarrhea using the Society for Healthcare Epidemiology of America definition in the follow-up period for those patients who initially experienced a clinical cure. Patients were followed for 40 days from the time of recruitment. Patients recorded a daily stool and symptom diary using the Bristol stool score, a validated measure of stool consistency [14] , and were contacted daily throughout the treatment period and at 7 and 30 days after the completion of treatment to review their diaries. During daily visits and telephone calls, study staff assessed the compliance by reviewing medical records in which nurses recorded medication administration (for inpatients only) and by discussing with patients how many capsules were taken on a daily basis (for inpatients and outpatients). The study coordinator recorded the number of capsules taken, as well as the date of missed doses, and reminded patients to continue taking the study medications as instructed. Drug accountability analysis was performed after the treatment period by the study staff on the basis of the number of capsules dispensed and the number of capsules returned. In addition to the scheduled follow-up contacts, patients contacted study personnel when they had recurrent symptoms; stool samples were obtained and sent to the local microbiology laboratory for confirmation of C. difficile toxins A and B by the enzyme immunoassay. Specific outcomes were defined as the time to resolution of symptoms (expressed in days), the clinical relapse rate, and adverse reactions related to treatment in each arm. Adverse reactions were assessed by monitoring clinical manifestations.
Data analysis and sample size calculation. Outcomes were analyzed by intention-to-treat analysis, and efficacy was determined by use of the Kaplan-Meier method and the log-rank test. All analyses were 2-tailed, and a P value !.05 indicated statistical significance. The statistical software used for the analysis was SPSS, version 11.5 (SPSS). To identify an absolute difference in relapse rates of 20% between the groups, an estimated sample size of 100 patients (50 patients per treatment arm) was required for the study to have 80% power. An analysis was performed after the recruitment of 39 patients, because the grant period of 1 year was complete, and no further funding was available. The analysis allowed us to assess whether to apply for further funds or to abandon the study. We determined that there was little likelihood of demonstrating benefit from treatment with rifampin as an adjunct to metronidazole for CDAD; therefore, we decided to halt the study.
RESULTS
During patient recruitment from February 2004 through March 2005, a total of 279 positive diagnoses of CDAD were reported.
A total of 212 patients were excluded from the study, because they did not fulfill the inclusion and exclusion criteria. A total of 39 of the 67 eligible patients consented to participate and were enrolled in the study. Twenty patients were randomly assigned to the metronidazole group, and 19 patients were randomly assigned to the metronidazole and rifampin group. Thirty-seven participants were inpatients, and 2 participants were outpatients. Other patient characteristics were similar between the 2 treatment groups and are shown in table 1.
A total of 32 (82%) of 39 patients were compliant with therapy, defined as 170% adherence to the assigned 10-day treatment regimen. Reasons for discontinuation of study medication included the following: headache, epigastric pain, or nausea and vomiting (2 patients); death (1 patient); having a condition too unstable for continued participation and being withdrawn by the most responsible physician (1 patient); and being discharged from the hospital without study medications (2 patients). One patient was noncompliant with study medication, and the reasons for the patient's noncompliance were unknown. A total of 32 (82%) of 39 patients completed the 30-day follow-up period. Seven patients died (2 patients died during the treatment period, and 5 patients died during the follow-up period).
Outcomes among treatment groups are outlined in table 2. Intention-to-treat analysis was performed, and all 39 patients were analyzed for study outcomes. The median time to improvement was 6.5 days for patients receiving metronidazole, compared with 9.0 days for patients receiving metronidazole and rifampin ( ; figure 1) . The clinical relapse rate in P p .74 the metronidazole group was 5 (38%) of 13 patients, compared with 5 (42%) of 12 patients in the metronidazole and rifampin group ( ). The time to clinical relapse in the metroni-P p 1.0 dazole group was 16 days, compared with 26 days in the metronidazole and rifampin group ( ; figure 2 ). The number P p .23 of laboratory-confirmed relapses was 4 (20%) of 20 in the metronidazole group, compared with 2 (11%) of 19 in the metronidazole and rifampin group ( ; figure 3) . P p .66 There was no statistically significant difference between groups for nonfatal adverse effects. Rash, nausea, and/or vomiting were experienced by 8 (40%) of 20 patients in the metronidazole group, compared with 7 (37%) of 19 patients in the metronidazole and rifampin group ( ). More specifically, P p .55 nausea was experienced by 5 (25%) of 20 patients in the metronidazole group, compared with 4 (21%) of 19 patients in the metronidazole and rifampin group ( ). Vomiting was P p .54 experienced by 2 (10%) of 20 patients in the metronidazole group, compared with 4 (21%) of 19 patients in the metronidazole and rifampin group ( ). Rash was experienced P p .31 by 2 (10%) of 20 patients in the metronidazole group, compared with 1 (5%) of 19 patients in the metronidazole and rifampin group ( ). P p .52 During the 10-day treatment period, 0 (0%) of 20 patients died in the metronidazole group, compared with 2 (11%) of 19 patients in the metronidazole and rifampin group. In total, 7 patients died within 40 days after enrollment, including 1 (5%) of 20 patients in the metronidazole group and 6 (32%) of 19 patients in the metronidazole and rifampin group ( ), as indicated in table 3 and figure 4. One patient in P p .04 the metronidazole and rifampin arm who died, however, never received rifampin.
DISCUSSION
Interest in exploring new treatment options for CDAD has been generated by the high relapse rate associated with conventional treatment (i.e., treatment with metronidazole or vancomycin). In this study, patients treated with metronidazole and rifampin, compared with patients who were given metronidazole alone, had a similar median time to symptom improvement (9 days vs. 6.5 days) and a similar rate of laboratory-confirmed relapse (17% vs. 31%). These outcomes for patients receiving metronidazole are similar to those described elsewhere [15] . However, it is possible that some cases of relapse may have been secondary to exogenous reinfection.
Metronidazole is well absorbed after oral administration, and high concentrations are found in stool during acute episodes of CDAD [16] . Metronidazole has been considered to be the drug of choice for the treatment of CDAD, and our results did not demonstrate therapeutic benefit with adjunctive rifampin therapy. The clinical cure rate in our study was 65% in the metronidazole group, compared with 63% in the rifampin and metronidazole group. We demonstrated a lower clinical cure rate than the 95% clinical cure rate previously reported for patients who received a 10-day course of metronidazole [12] .
Our study was halted early because of study futility; therefore, we did not reach our calculated sample size. Interim analysis demonstrated a very small probability of success and the possibility of treatment harm with adjunctive rifampin therapy. A large percentage of our study population were hospital inpatients (95%) with multiple comorbidities; therefore, we are unable to generalize our results to outpatients or to less ill patients treated for CDAD, for whom rifampin therapy may prove beneficial. The high mortality rate in our study population is likely to be attributable to the fact that the patients were elderly and had multiple severe comorbidities.
Patients receiving tacrolimus, cyclosporine, or warfarin therapy were excluded from the study because of rifampin's capacity to affect liver metabolism and alter serum drug concentrations. Patients reported the resolution of symptoms (diarrhea) using the Bristol stool score [14] . Because of the scale's subjective nature, reporting accuracy may be different from patient to patient. Furthermore, a patient's medical condition or treatment (e.g., nasogastric feeds) may have influenced diarrhea resolution and patient reporting.
In this study, we demonstrated that adjunctive rifampin treatment for 10 days, compared with treatment with metronidazole alone, was associated with a similar time to symptom improvement, a similar time to first relapse, and a similar proportion of patients with relapse by 40 days after enrollment. There were fewer laboratory-confirmed relapses by 40 days after enrollment in the metronidazole and rifampin group, but this difference was not statistically significant. Nonfatal adverse effects were similar between the 2 study arms. We report a higher number of deaths in the metronidazole and rifampin group, compared with the metronidazole group, but none of the deaths could be attributed to the combination of metronidazole and rifampin (table 3). We conclude that there is no role for routine rifampin therapy as an adjunct to metronidazole therapy. The cure rate among patients who receive the standard therapy of metronidazole remains unacceptably low, especially among hospitalized patients, and better treatments are urgently needed.
